finding one in a million to treat millions
At Variant we are searching the globe for people who are outliers for traits of medical relevance and using genomics to identify the genes and pathways driving these traits.
We are committed to doing so in a way that respects the privacy, beliefs, and cultures of our study participants while at the same time benefiting them. This unique approach will uncover the targets for tomorrow’s drugs and advance much-needed therapies to market.
Akhila has over 10 years of biotech executive experience. She previously was a VP at SIGA Technologies that brought an infectious disease drug to market with over $500M in sales. She sourced new medical technologies for the Pentagon serving as the Special Assistant to the Assistant Secretary of Defense for Health Affairs and received the Office of the Secretary of Defense Medal for Exceptional Public Service. She completed her MD at Columbia University and BA in Human Biology from Stanford University.
Kaja has spent her career developing novel sequencing platforms. She previously co-founded and was the Chief Science Officer of Gencove, a technology company that was the first to offer commercial low-pass DNA sequencing. She developed molecular sequencing technologies as a post-doc at the New York Genome Center, completed her PhD in molecular biology at Cold Spring Harbor Laboratory, and has MS and undergrad degrees from the University of Warsaw.
Stephane has deep expertise analyzing the genome. He was previously a post-doc at Columbia University, where he was a lead analyst in the GTEx project, the largest study of how genetic variation affects gene expression. His work has been published in top scientific journals including Nature, Nature Genetics, and Cell, and he was a recipient of a K99 award from the National Human Genome Research Institute. He also co-founded Fiix Software, which develops cloud-based asset management solutions. He completed his PhD in genetics at Cold Spring Harbor Laboratory and undergrad at the University of Guelph.
Josh co-founded Lux Capital, with $2.4B under management, to support scientists and entrepreneurs who pursue counter-conventional solutions to the most vexing puzzles of our time in order to lead us into a brighter future. Josh is a Director at Shapeways, 3Scan, Lux Research, Kallyope, and CTRL-labs, helped lead Lux’s investments in Planet, Echodyne, Clarifai and Authorea, co-founded Kurion, and is a founding investor and board member with Bill Gates in Kymeta. He graduated from Cornell University with a B.S. in Economics and Finance.
Our team is rapidly expanding, and we’re looking for people who aren't afraid to take on new challenges, and are as passionate about improving human health as we are.
Check out our careers page for more information.